Table 1. Study characteristics.
| Study | Year | Country | No. of patients (control/study) | IVIG-responsive | IVIG-resistant | ||
|---|---|---|---|---|---|---|---|
| Age (mo) | Sex, male/female | Age (mo) | Sex, male/female | ||||
| Lee et al.2) | 2014 | Korea | 91 (80/11) | 3.1±1.8 | 41/39 | 3.8±3.0 | 6/5 |
| Cho et al.3) | 2014 | Korea | 152 (135/17) | 34.035±30.15 | 75/60 | 35.845±21.65 | 9/8 |
| Sato et al.4) | 2013 | Japan | 105 (84/21) | 23.0±16.9 | 51/33 | 41.5±33.5 | 11/10 |
| Fu et al.5) | 2013 | China | 1,177 (966/211) | - | 602/364 | - | 144/67 |
| Yoshimura et al.6) | 2013 | Japan | 80 (63/17) | 2.3±1.6 | 46/17 | 1.3±1.0 | 8/9 |
| Park et al.7) | 2013 | Korea | 309 (279/30) | 26 (13-44)* | 142/137 | 27.5 (16.8-38.3)* | 19/11 |
| Kim et al.8) | 2011 | Korea | 129 (107/22) | 29.0±20.8 | 57/50 | 35.9±28.6 | 15/7 |
| Do et al.9) | 2010 | Korea | 77 (64/13) | 30.5±22.5 | 43/21 | 32.6±25.3 | 8/5 |
| Kuo et al.10) | 2010 | Taiwan | 131 (111/20) | 1.60±1.38 | 78/33 | 1.63±0.87 | 15/5 |
| Sleeper et al.11) | 2010 | USA | 198 (171/27) | 3.7±2.5 | 103/68 | 3.2±2.2 (2.8) | 22/5 |
| Sano et al.12) | 2006 | Japan | 112 (90/22) | 2.2±1.6 | - | 2.3±1.8 | - |
| Kobayashi et al.13) | 2006 | Japan | 204 (162/42) | 28.4±20.5 | 102/102 | 28.4±20.5 | 21/21 |
Values are presented as mean±standard deviation unless otherwise indicated.
IVIG, intravenous immunoglobulin.
*Range.